Evaluation of Dyslipidaemia and Atherogenic Index in Patients with Chronic Kidney Disease in a Nigerian Tertiary Health Facility

O. R. Omole

Department of Nursing, Coventry University, United Kingdom.

I. E. Okeji

Department of General Medicine, North Cumbria Integrated Care, NHS Foundation Trust, United Kingdom.

J. E. Odarah

JBS Gerontology Centre and Medicare Services, Lekki, Lagos State, Nigeria.

U. J. Ogbonna

Clinical Class 3, Abia State University Teaching Hospital, Aba, Nigeria.

J. E. Areh

Department of Emergency Medicine, Warrington and Halton Hospitals, NHS Foundation Trust, United Kingdom.

D. O. Anele

Department of Pharmacology and Therapeutics, Gregory University, Uturu, Abia State, Nigeria.

N. B. Zurmi

School of Public Health, Texila American University, Guyana.

C. E. Ijioma

Department of Family Medicine, Abia State Specialist Hospital and Diagnostic Centre, Umuahia, Nigeria.

A. C. Amuta

Prince George’s County Health Department, 1701 McCormick Drive, USA.

J. O. Orji

Department of Acute Medicine, University Hospital of Derby and Burton, NHS Foundation Trust, United Kingdom.

J. C. Okereke

Department of Paedriatrics, Federal Medical Centre, Asaba, Delta State, Nigeria.

O. Austin-Jemifor

Internal Medicine, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, NHS Foundation Trust, UK.

U. E. Ojumonu

Abia State University Teaching Hospital, Aba, Nigeria.

I. O. Abali

Department of Surgery, Abia State University, Uturu, Nigeria.

A. I. Airaodion *

Department of Biochemistry, Federal University of Technology, Owerri, Imo State, Nigeria.

*Author to whom correspondence should be addressed.


Background: Chronic kidney disease (CKD) is a global health concern associated with significant morbidity and mortality. Dyslipidaemia is a common complication of CKD, contributing to cardiovascular events. This study aims to assess dyslipidaemia and the atherogenic index in CKD patients at various stages in a tertiary health facility in Southern Nigeria.

Methods: A cross-sectional case-control study was conducted, enrolling 200 participants, including 50 healthy individuals as controls and 150 CKD patients (stages 3 to 5). Exclusion criteria encompassed viral hepatitis, HIV, malignancy, life-threatening illnesses, liver diseases, and cerebrovascular diseases. Ethical approval and informed consent were obtained. Sociodemographic and clinical data were collected using a self-administered questionnaire. Blood samples were analyzed for urea, creatinine, triglycerides, total cholesterol, and HDL-Cholesterol. Calculations included LDL, VLDL, LDL/HDL ratio, and the atherogenic index. eGFR was measured using the MDRD equation. Statistical analysis utilized SPSS (version 22.0) with one-way ANOVA.

Results: CKD patients exhibited significant alterations in renal parameters compared to controls (p < 0.05). The lipid profile of CKD patients showed elevated total cholesterol, reduced HDL-Cholesterol, increased LDL-Cholesterol, elevated LDL/HDL ratio, elevated VLDL-Cholesterol, and elevated triglycerides (p < 0.05). Atherogenic index significantly increased with advancing CKD stages (p < 0.05).

Conclusion: This study highlights the prevalence of dyslipidaemia in CKD patients, with a notable increase in the atherogenic index as the disease progresses. These findings underscore the importance of monitoring lipid profiles in CKD patients for cardiovascular risk assessment. Further research is warranted to explore interventions targeting dyslipidaemia in this population.

Keywords: Atherogenic Index, cardiovascular risk, chronic kidney disease, dyslipidaemia, lipid profile

How to Cite

Omole , O. R., Okeji , I. E., Odarah , J. E., Ogbonna , U. J., Areh , J. E., Anele , D. O., Zurmi , N. B., Ijioma , C. E., Amuta , A. C., Orji , J. O., Okereke , J. C., Austin-Jemifor , O., Ojumonu , U. E., Abali , I. O., & Airaodion , A. I. (2024). Evaluation of Dyslipidaemia and Atherogenic Index in Patients with Chronic Kidney Disease in a Nigerian Tertiary Health Facility. International Journal of Advances in Nephrology Research, 7(1), 26–33. Retrieved from https://journalijanr.com/index.php/IJANR/article/view/53


Download data is not yet available.


National Kidney Foundation. Chronic Kidney Disease; 2020. Available:https://www.kidney.org/atoz/content/about-chronic-kidney-disease

Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, Xiang J. US renal data system annual data report: Epidemiology of kidney disease in the United States. American Journal of Kidney Diseases. 2017;69(3):A7-A8.

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F. Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology, 2016;17(7):2034-2047.

Tsimihodimos V, Elisaf M. Lipids and renal disease: Cause or effect? World Journal of Nephrology. 2018;7(5):58–63. Available:https://doi.org/10.5527/wjn.v7.i5.58

Toth PP, Potter D, Ming EE, Preiss R, Johnson RD, Lipids in renal disease advisory group. The impact of severe renal impairment on the lipid composition of lipoproteins. Journal of Clinical Lipidology. 2019;13(1):42-49. Available:https://doi.org/10.1016/j.jacl.2018.11.004

Smith ER, Tomlinson LA, Ford ML. Dyslipidaemia in chronic kidney disease: Causes and consequences. Nature Reviews Nephrology. 2020;16(2):87–99.

Johnson L, Eckardt KU, Lameire N. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2017 clinical practice guideline update. Annals of Internal Medicine. 2020;172(3):200–213.

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A Review. JAMA. 2022; 322(13):1294–1304.

Wang X, Zhou M, Wang Z, Liu F. Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: A cross-sectional study. Lipids in Health and Disease. 2018;17(1):284.

Futuhi F, Naghibzadeh Tahami A, Azmandian J, Saber A. The effects of curcumin-containing supplementations on inflammatory markers and lipid profiles in patients with chronic kidney diseases: A systematic review and meta analysis of randomized controlled trials. J. Complement. Integr. Med. 2022;19: 531–541.

He Y, Lang X, Cheng D, Yang Z. Curcumin z of the MTOR/HIF-1α/VEGF Signaling Pathway. Biol. Pharm. Bull. 2019;42:886–891

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 Countries. Circulation. 2019;134(6): 441–450.

Choi YJ, Yoon YS, Choi HS, Kim, HS. Atherosclerosis risk in chronic kidney disease: the dyslipidemia factor. Endocrinology and Metabolism. 2018;33 (2):149–158.

Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases. 2021;77(6):934–947.

Stevens, L. A., Coresh, J., Feldman, H. I., Greene, T., Lash, J. P., Nelson, R. G., Rahman, M., Deysher, A. E., Zhang, Y. L., & Schmid, C. H. (2019). Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney International. 2019;79(5):555–562.

Garcia M, Mulvagh SL, Merz CNB. Cardiovascular disease in women with chronic kidney disease. Nature Reviews Nephrology. 2017;13(3):172–183.

Li X, Zhou M, Wang X, Liu F. Dyslipidemia and cardiovascular risk in chronic kidney disease: A cross-sectional study. Frontiers in Cardiovascular Medicine. 2021;8: 636405.

Airaodion AI, Ogbuagu U, Ekenjoku JA, Ogbuagu EO, Airaodion EO. Hyperglycemic and hyperlipidemic effect of some coca-cola soft drinks in Wistar rats. Acta Scientific Nutritional Health. 2019;3(12):114-120.

Raju D, Kedari GSR. Assessment of dyslipidemia and atherogenic index of plasma in stage 3 to Stage 5 chronic kidney disease. International Journal of Health Sciences. 2022;6(S1):2232–2240. Available:https://doi.org/10.53730/ijhs.v6nS1.5158

Airaodion AI, Ogbuagu EO, Ekenjoku JA, Okoroukwu VN, Ogbuagu U. Bigi soft drinks might induce hyperglycemia and hyperlipidemia in Wistar rats. International Journal of Research and Reports in Hematology. 2019;2(4):1-10.

Ogbuagu EO, Airaodion AI, Ogbuagu U, Airaodion EO. Effect of methanolic extract of Vernonia amygdalina leaves on glycemic and lipidaemic indexes of Wistar rats. Asian Journal of Research in Medical and Pharmaceutical Sciences. 2019;7(3): 1-14.

Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 2018;334 (1):13–18.

Kim SM, Kim HJ, Kim DJ, Kim IJ. Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Research and Clinical Practice. 2022;41(1):20–32.

Amann K, Benz K, Kretzler M. The diagnosis of chronic kidney disease. Dtsch Arztebl Int. 2020;117(43):710–717.